Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 6/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.44 |
| ▸ | MAT2A | P31153 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.33 |
| ▸ | FLT3 | P36888 | 3/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28115998 | 1.00 | PRKCQ (0.44) | PRKCQPRKCDMAT2APTK2PTK2B | |
| SCHEMBL16822033 | 0.80 | PRKCQ (0.50) | PRKCQPRKCDMAT2ALRRK2 | |
| SCHEMBL16822057 | 0.80 | PRKCQ (0.50) | PRKCQPRKCDMAT2ALRRK2 | |
| SCHEMBL16835308 | 0.79 | PRKCQ (0.45) | PRKCQPRKCDMAT2APTK2ULK1 | |
| SCHEMBL16835307 | 0.79 | PRKCQ (0.45) | PRKCQPRKCDMAT2APTK2ULK1 | |
| SCHEMBL16822075 | 0.79 | PRKCQ (0.45) | PRKCQPRKCDMAT2APTK2ULK1 | |
| SCHEMBL28115997 | 0.78 | PRKCQ (0.44) | PRKCQPRKCDMAT2APTK2PTK2B | |
| SCHEMBL16822136 | 0.77 | PRKCQ (0.44) | PRKCQPRKCDMAT2APTK2PTK2B | |
| SCHEMBL25209667 | 0.71 | GSK3A (0.42) | PTK2PTK2BKCNH2ULK1KDR | |
| SCHEMBL30396196 | 0.71 | GSK3A (0.42) | PTK2PTK2BKCNH2ULK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3736268-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3082819-B1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2020-06-17 | — | — | EP | disclosed |
| US-9783505-B2 | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-9556126-B2 | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160354374-A1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2016-12-08 | — | — | US | disclosed |
| US-9156798-B2 | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150246890-A1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS LLC | 2015-09-03 | — | — | US | disclosed |
| US-20150175557-A1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS LLC | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246890-A1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | PRKCQ, PRKCH, PRKCE | PRKCQ 1/4885PRKCD 9/4885MAT2A 725/4885 |
| US-20160354374-A1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | PRKCQ, PRKCH, PRKCE | PRKCQ 1/4885PRKCD 9/4885MAT2A 725/4885 |
| US-20150175557-A1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | PRKCQ, PRKCH, PRKCE | PRKCQ 1/4885PRKCD 9/4885MAT2A 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.